Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation

Gastroenterology. 2022 Apr;162(4):1160-1170.e1. doi: 10.1053/j.gastro.2021.12.286. Epub 2022 Jan 5.

Abstract

Background & aims: Hepatocellular carcinogenesis of hepatitis B virus (HBV) infection may arise from integration of viral DNA into the host genome. We aimed to gauge the effect of viral inhibition on transcriptionally active HBV-host integration events and explore the correlation of viral integrations with host gene dysregulation.

Methods: We leveraged data and biospecimens from an interventional trial, in which patients with HBV viremia above 2000 IU/mL and minimally raised serum liver enzyme were randomized to receive tenofovir disoproxil fumarate (TDF) or placebo for 3 years. Total RNA-sequencing was performed on paired liver biopsies taken before and after the 3-year intervention in 119 patients. Virus-host chimeric reads were captured to quantify the number of distinct viral integrations. Dysregulation of a host gene disrupted by viral integration was defined by aberrant expression >2 standard deviations away from samples without viral integration.

Results: The TDF (n = 64) and placebo groups (n = 55) were comparable at baseline. Expressed viral integrations were detected in all pre- and posttreatment samples. The number of distinct viral integrations significantly correlated with circulatory biomarkers indicative of viral activities including HBV DNA, RNA, and viral antigens (P < .0003 for all correlations). Moreover, TDF vs placebo achieved a significantly greater reduction in distinct viral integrations, with 3.28-fold and 1.81-fold decreases in the expressed integrations per million reads, respectively (analysis of covariance, P = .037). Besides, viral integrations significantly correlated with host gene dysregulation.

Conclusion: Inhibition of viral replication reduces the number of transcriptionally active distinct HBV-host DNA integrations in patients with substantial viremia. Given the mutagenic potentials of viral integrations, such treatment effects should be considered in patient management.

Keywords: Antiviral Treatment; Chronic Hepatitis B; Hepatocellular Carcinogenesis; Transcriptome Analysis; Viral Integration.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • DNA, Viral / genetics
  • Hepatitis B virus
  • Hepatitis B* / drug therapy
  • Hepatitis B* / genetics
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • RNA
  • Tenofovir / therapeutic use
  • Treatment Outcome
  • Viral Load
  • Viremia / drug therapy
  • Viremia / genetics
  • Virus Integration
  • Virus Replication

Substances

  • Antiviral Agents
  • DNA, Viral
  • RNA
  • Tenofovir